Skip to main content

Table 1 Demographic and baseline characteristics

From: Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

  Pateclizumab ADA Placebo All patients
(n = 85) (n = 85) (n = 44) (n = 214)
Age (yr)
Mean (SD) 50.2 (13.1) 50.6 (13.3) 48.8 (14.0) 50.1 (13.3)
Median 51.0 52.0 48.5 51.0
Range (min, max) 18-75 20-73 23-75 18-75
Age group
<65 yr (%) 72 (84.7%) 69 (81.2%) 36 (81.8%) 177 (82.7%)
≥65 yr (%) 13 (15.3%) 16 (18.8%) 8 (18.2%) 37 (17.3%)
Sex
Female 78 (91.8%) 68 (80.0%) 37 (84.1%) 183 (85.5%)
Male 7 (8.2%) 17 (20.0%) 7 (15.9%) 31 (14.5%)
Race
White 53 (62.4%) 48 (56.5%) 29 (65.9%) 130 (60.7%)
Black 1 (1.2%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
American Indian or Alaska Native 1 (1.2%) 3 (3.5%) 0 (0.0%) 4 (1.9%)
Asian (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Native Hawaiian or other Pacific Islander (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Not available 30 (35.3%) 34 (40.0%) 15 (34.1%) 79 (36.9%)
Region
US and Western Europe 12 (14.1%) 12 (14.1%) 6 (13.6%) 30 (14.0%)
Latin America and Eastern Europe 73 (85.9%) 73 (85.9%) 38 (86.4%) 184 (86.0%)
BMI (kg/m2)
Mean (SD) 27.114 (5.075) 27.309 (4.194) 26.903 (5.547) 27.148 (4.830)
Weight (kg)
Mean (SD) 68.66 (14.88) 69.52 (12.75) 69.15 (22.61) 69.11 (15.96)
  1. ADA, adalimumab; BMI, body mass index; min, max, minimum, maximum; SD, standard deviation.